JPMorgan Chase & Co. Sells 28,795 Shares of Unum Group (NYSE:UNM)

JPMorgan Chase & Co. lowered its stake in Unum Group (NYSE:UNM - Free Report) by 4.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 623,724 shares of the financial services provider's stock after selling 28,795 shares during the quarter. JPMorgan Chase & Co. owned about 0.34% of Unum Group worth $37,074,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Capital Performance Advisors LLP bought a new stake in Unum Group in the 3rd quarter valued at $31,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Unum Group in the 3rd quarter valued at about $37,000. V Square Quantitative Management LLC lifted its holdings in shares of Unum Group by 38.2% in the third quarter. V Square Quantitative Management LLC now owns 702 shares of the financial services provider's stock valued at $42,000 after purchasing an additional 194 shares in the last quarter. William B. Walkup & Associates Inc. bought a new position in shares of Unum Group during the second quarter worth about $44,000. Finally, Quarry LP grew its holdings in shares of Unum Group by 4,794.7% during the third quarter. Quarry LP now owns 930 shares of the financial services provider's stock worth $55,000 after buying an additional 911 shares in the last quarter. Institutional investors and hedge funds own 86.57% of the company's stock.

Unum Group Stock Performance

Unum Group stock traded up $0.09 during mid-day trading on Tuesday, hitting $73.36. 1,085,307 shares of the company's stock traded hands, compared to its average volume of 1,115,252. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.28 and a quick ratio of 0.28. The firm has a 50 day simple moving average of $72.50 and a two-hundred day simple moving average of $61.72. Unum Group has a fifty-two week low of $44.83 and a fifty-two week high of $77.63. The stock has a market cap of $13.40 billion, a price-to-earnings ratio of 7.94, a P/E/G ratio of 1.06 and a beta of 0.81.

Unum Group (NYSE:UNM - Get Free Report) last posted its earnings results on Tuesday, October 29th. The financial services provider reported $2.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.10 by $0.03. Unum Group had a net margin of 13.76% and a return on equity of 15.21%. The company had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.26 billion. During the same quarter last year, the company posted $1.94 EPS. Unum Group's quarterly revenue was up 4.0% compared to the same quarter last year. On average, research analysts expect that Unum Group will post 8.54 EPS for the current fiscal year.

Unum Group Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 15th. Stockholders of record on Friday, October 25th were given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 2.29%. The ex-dividend date of this dividend was Friday, October 25th. Unum Group's payout ratio is 18.18%.

Analyst Ratings Changes

Several equities research analysts have commented on UNM shares. Wells Fargo & Company boosted their target price on Unum Group from $69.00 to $71.00 and gave the company an "overweight" rating in a research note on Thursday, October 10th. Piper Sandler increased their target price on shares of Unum Group from $74.00 to $82.00 and gave the stock an "overweight" rating in a report on Wednesday, December 18th. Morgan Stanley lifted their price target on shares of Unum Group from $62.00 to $64.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 30th. Truist Financial increased their price objective on shares of Unum Group from $70.00 to $75.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. Finally, UBS Group upgraded Unum Group to a "hold" rating in a research note on Wednesday, October 9th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Unum Group presently has an average rating of "Moderate Buy" and a consensus price target of $74.55.

Insider Activity

In other Unum Group news, EVP Elizabeth Claire Ahmed sold 5,000 shares of the business's stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $64.16, for a total value of $320,800.00. Following the completion of the sale, the executive vice president now owns 58,741 shares of the company's stock, valued at $3,768,822.56. The trade was a 7.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Timothy Gerald Arnold sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $76.92, for a total transaction of $769,200.00. Following the transaction, the executive vice president now owns 54,827 shares in the company, valued at approximately $4,217,292.84. The trade was a 15.43 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 107,914 shares of company stock valued at $7,998,745. 0.93% of the stock is owned by insiders.

About Unum Group

Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, Poland, and internationally. It operates through Unum US, Unum International, Colonial Life, and Closed Block segment. The company offers group long-term and short-term disability, group life, and accidental death and dismemberment products; supplemental and voluntary products, such as individual disability, voluntary benefits, and dental and vision products; and accident, sickness, disability, life, and cancer and critical illness products.